| AMGN34 Stock | | | BRL 63.60 0.14 0.22% |
Director
Ms. Ellen J. Kullman is an Independent Director of the Company. Ms. Kullman is the Director of Amgen Inc. Ms. Kullman has served as a director of the Company since October 14, 2016. Ms. Kullman was first identified to the Governance and Nominating Committee as a potential director candidate by the Companys outside search firm. Ms. Kullman is the former President, Chair and Chief Executive Officer of E.I. du Pont de Nemours and Company, or DuPont, a science and technologybased company, where she served from January 2009 to October 2015. Prior to this, Ms. Kullman served as President of DuPont from October 2008 to January 2009. From June 2006 through September 2008, she served as Executive Vice President of DuPont. Prior to that, Ms. Kullman was Group Vice President, DuPont Safety and Protection. Ms. Kullman was a director of United Technologies Corporationrationration, a technology products and services company, since 2011, serving on its Committee on Compensation and Executive Development and Chairing its Committee on Governance and Public Policy. Ms. Kullman was a director of Goldman Sachs Group, Inc., an investment banking firm, since December 2016, serving on its Compensation, Corporationrationrate Governance and Nominating, and Risk Committees. Ms. Kullman served as a director of General Motors, from 2004 to 2008, serving on its Audit Committee. Ms. Kullman joined the board of directors of Dell Technologies, a privatelyheld technology company, and the Temasek Americas Advisory Panel of Temasek Holdings Limited, a privatelyheld investment company based in Singapore since 2017.
| Age | 63 |
| Tenure | 8 years |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Kullman received a bachelor of science in mechanical engineering degree from Tufts University and a master’s degree from the Kellogg School of Management at Northwestern University.
Amgen Management Efficiency
The company has return on total asset
(ROA) of
0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.
Amgen Inc has accumulated 37.35
B in total debt. Amgen Inc has a current ratio of 1.5, which is within standard range for the sector. Debt can assist Amgen until it has trouble settling it off, either with new capital or with free cash flow. So, Amgen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amgen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amgen to invest in growth at high rates of return. When we think about Amgen's use of debt, we should always consider it together with cash and equity.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. AMGEN DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 24200 people. Amgen Inc (AMGN34) is traded on Sao Paulo Exchange in Brazil and employs 25,200 people.
Management Performance
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, Vice President - Finance, Chief Accounting Officer | |
| Nancy Grygiel, Sr Officer | |
| David Reese, Executive Vice President - Research and Development | |
| Tyler Jacks, Independent Director | |
| Gregory Garland, Independent Director | |
| Charles Holley, Independent Director | |
| Esteban Santos, Executive Vice President Operations | |
| Jonathan Graham, Senior Vice President General Counsel, Secretary | |
| Mike Zahigian, VP Officer | |
| Ellen Kullman, Independent Director | |
| Arvind Sood, IR Contact Officer | |
| Ronald Sugar, Independent Director | |
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | |
| Murdo Gordon, Executive Vice President of Global Commercial Operations | |
| Peter Griffith, Chief Financial Officer, Executive Vice President | |
| Wanda Austin, Independent Director | |
| Robert Eckert, Lead Independent Director | |
| Lori Johnston, Senior Vice President - Human Resources | |
| Brian Druker, Independent Director | |
| Cynthia Patton, Senior Vice President Chief Compliance Officer | |
| Robert Williams, Independent Director | |
| Amy Miles, Independent Director | |
| Fred Hassan, Independent Director | |
| David Piacquad, Senior Vice President - Business Development | |
| David MD, Ex RD | |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Amgen Stock
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
You can also try the
Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.